Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Teduglutide (Revestive) in Adult and Pediatric Patients With Short Bowel Syndrome in Argentina
Latest Information Update: 21 Jul 2023
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions
- Sponsors Takeda
- 18 Jul 2023 Status changed from recruiting to completed.
- 09 Nov 2022 Planned number of patients changed from 28 to 40.
- 09 Nov 2022 Planned End Date changed from 5 Nov 2022 to 22 May 2023.